Limosilactobacillus reuteri

Studied for: Diverticular Disease

Diverticular Disease

What the research found

Limosilactobacillus reuteri ATCC PTA 4659 decreased C-reactive protein by 58.8% versus 40% with placebo at 72 hours in 119 acute uncomplicated patients.

Dose used in studies

oral adjunct twice daily for 10 continuous days

References

Ojetti2022

Not medical advice

Trials are run on specific people, for specific reasons, over a set period. Your medications, conditions and bloodwork can change what is safe for you. Ask a doctor or pharmacist before starting.